Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
REPEVAX after REVAXIS · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| REPEVAX® after REVAXIS® | EXPERIMENTAL | REVAXIS® at Visit 1 (Day 0) and REPEVAX®) at Visit 2 (Day 28). |
| REPEVAX® after Placebo | ACTIVE_COMPARATOR | Placebo at Visit 1 (Day 0) and REPEVAX®) at Visit 2 (Day 28). |
| Name | Type | Description |
|---|---|---|
| REPEVAX® after REVAXIS® | BIOLOGICAL | Tetanus, diphtheria, tetanus, pertussis (acellular, component) and poliomyelitis (inactivated) vaccine after tetanus, diphtheria, poliomyelitis (inactivated) |
| REPEVAX® after Placebo | BIOLOGICAL | Tetanus, diphtheria, tetanus, pertussis (acellular, component) and poliomyelitis (inactivated) vaccine after placebo |
Inclusion Criteria: * Healthy adult, with vaccination history (by written evidence) of a minimum of 5 doses of a tetanus, diphtheria and poliomyelitis containing vaccine as recommended in the French vaccination calendar at 18 years old, and a maximum of 8 doses. * Last dose of a tetanus and/or diph...
REPEVAX after REVAXIS refers to a sequential vaccination strategy in which the REPEVAX vaccine is given one month after the REVAXIS vaccine. It was studied in healthy adults aged 18 years and older in France. Sanofi is the developer.
Sanofi, which trades under the ticker SNY, is the developer of the REPEVAX after REVAXIS sequential vaccination strategy. Sanofi is the sponsor behind the clinical program evaluating REPEVAX administered one month following REVAXIS.
REPEVAX after REVAXIS has been evaluated in a Phase 3 clinical trial. The program is not currently listed with active trials; the single Phase 3 study has completed. It remains an investigational sequential vaccination strategy rather than a standalone approved product.
REPEVAX after REVAXIS was studied in one Phase 3 trial, NCT00400309, titled Safety of REPEVAX Given One Month After REVAXIS. The completed study enrolled 500 healthy adult volunteers aged 18 years and older in France and used a randomized, double-blind, active-controlled design.
No. REPEVAX after REVAXIS is not a separate product; it describes the sequence of administering REPEVAX one month after REVAXIS. The two vaccines are distinct, and the name refers to the combined sequential schedule studied in the Phase 3 trial.
The Phase 3 trial NCT00400309 was a randomized, double-blind, active-controlled study of 500 healthy adults aged 18 years and older. Participants received REPEVAX one month after REVAXIS, and the study was conducted in France. The trial has completed.